Patent · US Active

CD31 peptides in the treatment of thrombotic and autoimmune disorders

US9127086B2 · kind B2 · utility

2Cited by

1References

13Claims

0Family size

Assignee

INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) · FR

Inventors

Giuseppina Caligiuri · Paris, FR
Antonino Nicoletti · Paris, FR

Key dates

Filing date	Jun 30, 2009
Grant date	Sep 8, 2015
Priority date	—
Expiry date	Jul 18, 2030

Classification

Technology area (CPC G)Physics
CPC primaryG01N2500/10
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention stems from the finding that the extracellular domain of CD31 proteins present on blood leukocytes is shed and released in the circulation as a soluble form of CD31. The invention relates to peptides corresponding to fragments of CD31 that inhibit T-cell response, and to their use in the treatment of thrombotic disorders such as atherothrombosis and autoimmune disorders.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.